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Atrial Fibrillation – Clinical Issues
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Aims Amiodarone is associated with significant adverse effects. We hypothesized that episodic amiodarone treatment
would be associated with better quality of life (QoL) compared with continuous treatment in the prevention of
recurrent atrial fibrillation (AF).
Methods
and results
Quality of life was assessed in 158 patients from the Continuous vs. Episodic Prophylactic Treatment with Amiodar-
one for the Prevention of AF (CONVERT) study, using the Short Form (SF)-36 health survey and University of
Toronto AF Severity Scale (AF severity scale) questionnaires at baseline and 1 year. The episodic group received
amiodarone 1 month peri-cardioversion, the continuous group continued amiodarone. Patients were assessed for
major adverse events and maintenance of sinus rhythm during follow-up (i.e. no AF recurrences at every follow-
up visit). Quality of life (assessed by SF-36 and AF severity scale) was comparable between both treatment
groups at baseline and 12 months, with similar incidence rates of major adverse events. Fewer patients in the episodic
group had maintenance of sinus rhythm during follow-up [27 (36%) vs. 49 (59%), P ¼ 0.004]. In the episodic group,
maintenance of sinus rhythm was associated with a significant improvement on four SF-36 subscales and AF severity
scale at 12 months. In contrast, in the continuous group no significant differences in QoL were seen between patients
with continued maintenance of sinus rhythm compared with those with AF recurrence at the end of follow-up.
Conclusion Quality of life was comparable in the episodic and continuous treated group after 12 months of follow-up. Continued
maintenance of sinus rhythm was associated with an improvement in QoL in the episodic but not the continuous
treated group.
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Introduction
Atrial fibrillation (AF) is the most common occurring arrhythmia
and is associated with complaints such as palpitations, dyspnoea,
and fatigue. It may further lead to heart failure, stroke, and
death.1,2 Patients with symptomatic AF have been shown to have
impaired quality of life (QoL) compared with the general popu-
lation and even patients with other cardiac heart disease, such as
ischaemic heart disease, including myocardial infarction.3,4 The
most widely used tool to assess general health-related quality of
life (HRQL) is the Medical Outcomes Study Short Form (SF-36)
questionnaire,5 but more disease-specific measures of QoL for
AF have been developed such as the University of Toronto
Atrial Fibrillation Severity Scale to ascertain perceived AF sever-
ity.6,7 We and others have shown that restoration and maintenance
of sinus rhythm is associated with a significant increase in SF-36
subscales.4,8,9 Furthermore, symptomatic patients at baseline
were more likely to have improvement in SF-36 scores compared
with asymptomatic patients.9 Amiodarone is the most effective
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antiarrhythmic drug for achieving and maintaining sinus rhythm.8,9
Amiodarone, however, can cause major (non-)cardiac adverse
events, which might negate the positive benefit of maintaining
sinus rhythm. In the present study, we analysed QoL, measuring
general HRQL using the SF-36 and disease-specific measures of
QoL using the AF severity scale, in patients randomized to either
episodic or continuous amiodarone treatment for the prevention
of AF. Our hypothesis was that episodic amiodarone treatment
is associated with a lower major adverse event rate and a higher
QoL compared with continuous amiodarone treatment, while AF
is effectively suppressed although, at the cost of more electrical
cardioversions (ECVs). We furthermore wanted to investigate
the role of successful rhythm control on QoL in this population
of patients with persistent AF.
Methods
Patients
The present study was a predefined sub-study of the CONVERT study.
The methods and results have previously been described in detail.10
The study was approved by the institutional review boards of all par-
ticipating centres and patients gave written informed consent. In total
209 patients were included, 106 in the episodic amiodarone treatment
arm, and 103 in the continuous amiodarone treatment arm. In short,
patients were included in the presence of symptomatic AF recurrence
and were loaded with 600 mg oral amiodarone for 4 weeks prior to a
planned ECV and received a maintenance dose of 200 mg after achiev-
ing sinus rhythm. Patients were subsequently randomly assigned to
receive either episodic or continuous amiodarone treatment. In the
episodic treated group, patients continued amiodarone only 1 month
post-ECV, while patients in the continuous treated group continued
amiodarone throughout. In case of a recurrence of AF, patients
were re-loaded with amiodarone if it occurred under inadequate
(desethyl)amiodarone serum levels. AF was accepted in case of
adequate (desethyl)amiodarone levels of more than 2 mg/L at the
moment of a relapse. Patients were evaluated at the outpatient depart-
ment for rhythm control outcome and occurrence of the composite
primary endpoint (amiodarone- and underlying heart disease-related
major adverse events) throughout follow-up. For the purpose of the
present study, we defined patients to have maintenance of sinus
rhythm during follow-up if they did not have a recurrence of AF at
every follow-up visit.
Endpoints
The primary endpoint of the CONVERT study was a composite of
amiodarone-related (cardiovascular effects, hyper- and hypothyroid-
ism, pulmonary and hepatic toxicity, dermatological, ophthalmologic,
neurological, and gastrointestinal effects) and underlying heart
disease-related major events (hospital admission for heart failure,
thromboembolic complications, bleeding, myocardial ischaemia or
infarction, and death). In the parent study, no significant difference in
incidence rate of the primary endpoint was encountered between
both treatment strategies. For the present analysis, we included 158
patients who had completed at least 1 year of follow-up and com-
pleted the questionnaires at baseline and 12 months follow-up, 75 in
the episodic group and 83 in the continuous treated group, respect-
ively. Another 51 patients (31 episodic and 20 continuous treated
patients) either did not complete the questionnaires at either baseline
or 1 year or died during follow-up (n ¼ 9) and were excluded from the
present analysis. All the excluded patients did not differ significantly
from included patients at baseline and follow-up.
Quality of life questionnaire
Patients were asked to complete questionnaires at baseline
(i.e. inclusion visit and 4 weeks prior to ECV) and at 12 months
follow-up. Health-related quality of life was assessed using the
Medical Outcomes Study Short-Form health survey (SF-36) question-
naire. The SF-36 is a standardized, validated, generic health survey that
has been frequently used in arrhythmia studies. The SF-36 has been
translated and validated in the Netherlands.5 It contains eight sub-
scales. The subscales for assessing physical health are general health
perception, physical functioning, role limitations due to physical pro-
blems, and bodily pain. Mental health is assessed with the subscales
social functioning, role limitations due to emotional problems,
mental health, and vitality. Scores are transformed to a scale ranging
from 1 to 100, with lower scores representing a lower HRQL. Severity
of AF-related symptoms was assessed using Part C of the University of
Toronto AF Severity Scale (AF severity scale). This was developed as a
disease-specific instrument intended to measure the patient’s percep-
tion of severity of arrhythmia-related symptoms6 and represents an
AF-specific measurement of QoL. This is a seven-item checklist that
includes common AF symptoms (e.g. palpitations and dyspnoea).
Items are rated on a six-point scale. Scores range from 0 to 35, with
higher scores indicating greater AF symptom severity.
Statistical analysis
Baseline descriptive statistics are presented as the mean+ standard
deviation (SD) or median (range) for continuous variables and
numbers with percentages for categorical variables. At each measure-
ment point all subscales of the SF-36 and AF severity scale were
compared between the episodic and continuous treatment groups.
Within each treatment strategy, all subscales of the SF-36 and AF
severity scale were compared at baseline and 12 months between
patients who maintained sinus rhythm during follow-up and patients
with AF recurrence. For a comparison of scores between groups,
Student t-test was used for independent variables. For all analyses
of differences in scores at baseline and 12 months paired samples
Student t-tests were used. Effect size was calculated according to
Cohen11 by dividing the difference within the assigned treatment
strategies in the mean changes in SF-36 scores from baseline
divided by the pooled standard deviation to assess the clinical
importance of differences in SF-36 measures. P-value of ,0.05 was
deemed statistically significant. All analyses were performed on an
intention-to-treat basis. The statistical analyses were carried out
using the statistical program SPSS, version 16.0.
Results
The baseline characteristics of the patients in both treatment
groups were comparable with similar co-morbidity, except for
more chronic obstructive pulmonary disease in the episodic
group (Table 1). At baseline, the mean heart rate was comparable
between both treatment strategies (92+ 19 vs. 90+19 beats per
minute, P ¼ 0.5). Baseline SF-36 scores were compared with sex
and age matched controls. The controls scored significantly
higher on all but two subscales (mental health and bodily pain)
indicating that our study population represents a typical persistent
AF population (Figure 1A).
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The mean average heart rate during follow-up, irrespective of
rhythm, was significantly higher in the episodic compared with the
continuous group (72+11 vs. 66+ 12 beats per minute, P ¼
0.003). At 12 months, mean heart rate was also higher in the
episodic group (76+17 vs. 69+18 beats per minute, P ¼ 0.01)
with fewer patients on amiodarone therapy in the episodic group
[12 (16%) vs. 49 (59%), P, 0.001]. Patients who maintained sinus
rhythm during follow-up had a significant lower mean average heart
rate during follow-up (63+8 vs. 74+13 beats per minute, P,
0.001) and mean heart rate at 12 months (64+11 vs. 81+19
beats per minute, P, 0.001). No difference was observed in mean
average heart rate in patients with AF recurrence during follow-up
in both treatment strategies (75+12 vs. 73+13 beats per minute,
in the episodic and continuous group, respectively, P ¼ 0.5).
At 12 months of follow-up, a comparable number of patients
were on rate control medication [52 (70%) vs. 53 (64%) in the epi-
sodic vs. continuous group, P ¼ 0.4]. The majority of patients were
on continuous beta blocker medication from baseline [40 (53%) vs.
48 (58%) patients, P ¼ 0.6]. The mean duration of beta blocker use
was comparable (11.8+ 3.8 months vs. 10.7+5.4 months, P ¼
0.2). At 12 months of follow-up, only six patients remained on
digoxin from baseline. Digoxin was mostly discontinued early
during follow-up [1.2 (0.4–14.2) months in the episodic and 2.2
(0.7–13.1) months in the continuous group, P ¼ 0.9].
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .






Age (years) 68+9 65+9 0.1
Male, n (%) 43 (57%) 55 (67%) 0.3
AF/AFL, n (%) 74/1 (99/1%) 79/4 (95/5%) 0.3
Heart rate at baseline (beats per minute) 92+19 90+19 0.5
Total AF duration (days) 525 (55–11 750) 402 (48–9857) 0.8
Duration present episode of AF (days) 33 (0–255) 37 (0–917) 0.9
Complaints of AF, n (%) 71 (95%) 75 (90%) 0.4
Palpitations, n (%) 29 (39%) 33 (40%) 0.7
Dyspnoea, n (%) 52 (69%) 53 (64%) 0.9
Fatigue, n (%) 38 (51%) 42 (51%) 0.9
Underlying diseases
Coronary artery disease, n (%) 10 (13%) 13 (16%) 0.8
Valve disease, n (%) 5 (7%) 4 (5%) 0.7
Cardiomyopathy, n (%) 3 (4%) 2 (2%) 0.7
Hypertension, n (%) 33 (44%) 40 (48%) 0.6
History of chronic obstructive pulmonary disease, n (%) 13 (17%) 4 (5%) 0.01*
History of diabetes mellitus, n (%) 9 (12%) 9 (11%) 1.0
History of heart failure hospitalization, n (%) 2 (3%) 7 (8%) 0.2
NYHA class I for heart failure, n (%) 23 (31%) 30 (36%) 0.6
NYHA class II for heart failure, n (%) 52 (69%) 53 (64%)
Systolic blood pressure (mmHg) 136+17 137+18 0.6
Diastolic blood pressure (mmHg) 84+11 85+10 0.9
Left atrial size, long axis (mm) 47+6 45+5 0.04*
Left ventricular end diastolic diameter (mm) 50+8 51+7 0.7
Left ventricular end systolic diameter (mm) 35+10 35+7 0.7
Fractional shortening (%) 31+12 31+9 0.9
Medication at screening
Acenocoumarol, n (%) 72 (96%) 83 (100%) 0.2
Beta blocker, n (%) 45 (60%) 62 (75%) 0.1
Diuretics, n (%) 26 (35%) 30 (36%) 1.0
Angiotensin converting enzyme inhibitor, n (%) 35 (47%) 32 (39%) 0.3
Angiotensin II receptor blocker, n (%) 9 (12%) 10 (12%) 1.0
Digoxin, n (%) 22 (29%) 20 (24%) 0.5
Verapamil or diltiazem, n (%) 11 (15%) 14 (17%) 0.6
Statin, n (%) 10 (13%) 13 (16%) 0.8
AF, atrial fibrillation; AFL, atrial flutter; MI, myocardial infarction; NYHA, New York Heart Association; *statistically significant.
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Figure 1 SF-36 scores of persistent AF study patients at baseline compared with healthy gender and age matched controls (A); SF-36 scores
at baseline and 12 months follow-up in episodic and continuous treated groups (B); Atrial fibrillation severity scale scores at baseline and
12 months (C). AF, atrial fibrillation; SF-36, Short Form-36 health survey. *P, 0.05 study patients vs. healthy controls; **P, 0.05 episodic
vs. continuous group; #P, 0.05 episodic group: baseline vs. 12 months; $P, 0.05 continuous group: baseline vs. 12 months.
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Quality of life in episodic vs. continuous
treated group
Short Form-36 scores were comparable between the episodic and
continuous treated groups at baseline and 12 months (Figure 1B).
The only difference between treatment strategies was seen at
baseline on the subscale general health with a higher score in
the episodic group (57 vs. 50, P, 0.05, Figure 1B). In the episodic
group, an improvement after 12 months was seen on the subscale
vitality (þ8, P ¼ 0.03, Figure 1B). In the continuous group, an
improvement was seen on the subscales role limitations due to
physical problems and general health after 12 months (þ24, P ¼
0.001 and þ7, P ¼ 0.02, respectively, Figure 1B). The effect sizes
of changes (i.e. the measurement of the magnitude of a treatment
effect) in SF-36 scores within the treatment strategies were,
however, small and below 0.25 (i.e. one-fourth standard deviation).
Scores on the AF severity scale, indicating perceived severity of
AF-related complaints, were comparable at baseline and after
12 months in both treatment groups (Figure 1C).
The incidence of major adverse events was comparable between
the episodic and continuous treated groups during 12 months of
follow-up [19 (25%) vs. 20 (24%), P ¼ 0.9]. In 26 (16%) patients
an amiodarone-related major adverse event occurred [9 (12%)
vs. 17 (20%), P ¼ 0.1, in the episodic and continuous treated
group, respectively], with thyroid dysfunction being the most
prevalent. After 12 months, improvement on all SF-36 scales was
seen independent of the occurrence of an amiodarone-related
adverse event (data not shown). In total 13 (8%) patients encoun-
tered an underlying heart disease-related adverse event during
12 months of follow-up. Significantly more underlying heart
disease-related adverse events occurred in the episodic compared
with the continuous treated group [10 (13%) vs. 3 (4%), P ¼ 0.03].
Significant impairment was seen on the subscale bodily pain in
patients with an underlying heart disease-related major adverse
event compared with those without (P ¼ 0.04).
Rhythm control outcome and quality
of life
At the end of follow-up, in total 76 (48%) patients had maintained
sinus rhythm, i.e. had no recurrence of AF at every follow-up visit.
Episodic treatment was significantly less successful in achieving
maintenance of sinus rhythm after 12 months of follow-up [27
(36%) vs. 49 (59%) patients, P ¼ 0.004]. Median number of AF
recurrences during 12 months of follow-up was comparable
between both treatment groups [1 (1–2) in the episodic vs. 1
(1–3) in the continuous treated group, P ¼ 0.7]. Mean time to
first AF recurrence was also comparable between both treatment
groups and occurred relatively late (after 244+192 days in the
episodic vs. 320+ 157 days in the continuous treated group,
P ¼ 0.1). Within the treatment strategies there were significant
differences in QoL, assessed by SF-36 and AF severity scale. In
the episodic treated group, after 12 months of follow-up significant
improvement in QoL was seen in patients who maintained sinus
rhythm during follow-up compared with patients with AF recur-
rence. Improvement occurred on four SF-36 subscales [two sub-
scales assessing physical (physical functioning and role limitations
due to physical problems) and two assessing mental health
(social functioning and vitality)] (Figure 2). Furthermore, a signifi-
cantly larger decrease in severity of AF-related complaints as
assessed by the AF severity scale was observed in the episodic
group (Figure 1C). In contrast, in the continuous treated group
no significant differences in QoL were seen between patients
who maintained sinus rhythm during follow-up after 12 months
of follow-up compared with those with AF recurrence. Similar
scores on the SF-36 subscales (Figure 2) and comparable decrease
in severity of AF-related complaints were observed (Figure 1C).
Patients who maintained sinus rhythm throughout follow-up
seemed to show larger improvements in SF-36 scores in the episo-
dic compared with the continuous treated group, though it did not
reach statistical significance (Figure 2). Role limitations due to phys-
ical problems showed a significant larger improvement in case of
recurrent AF if patients were randomized to continuous amiodar-
one therapy (Figure 2). In both treatment groups, patients with
recurrence of AF showed a trend to worsening of role limitations
due to emotional problems (Figure 2).
Discussion
Our study shows that the assigned treatment strategy, episodic or
continuous amiodarone therapy, does not influence QoL, assessed
by SF-36 and AF severity scale, during 12 months of follow-up. Suc-
cessful rhythm control outcome, though, seems to influence QoL
positively, but only in the episodic group. Episodic amiodarone
treatment, however, was less effective in successful rhythm
control. In the present analysis, in continuously treated patients,
improvement in QoL between successfully and not successfully
treated patients was comparable.
Quality of life and amiodarone
Our persistent AF patients have lower SF-36 scores, compared
with healthy controls, which has consistently been shown in pre-
vious reports.4,6 Quality of life improved in both our amiodarone
rhythm control strategies, as assessed by SF-36 and the AF severity
scale, without significant differences between the episodic [amio-
darone 2 month peri-(re-) cardioversion] and continuous amiodar-
one treated groups. This may suggest that amiodarone itself does
not influence QoL. In line with our findings, Dorian et al.6 have
shown that amiodarone treatment improves SF-36 scores after
3 months of follow-up in a comparable study population. In that
study similar improvements in SF-36 scores were seen in the
sotalol and propafenone randomized treatment groups. In the
same study, scores on the AF severity scale also decreased as
well in the amiodarone, as in the sotalol and the propafenone ran-
domized patients.12 Another study comparing placebo, short-term
and long-term amiodarone treatment for the prevention of persist-
ent AF showed no differences in SF-36 scores between the three
groups during follow-up.13 Recently, Mark et al. compared SF-36
scores in heart failure patients, though mostly without AF,
treated with defibrillator or amiodarone therapy. Defibrillator
therapy improved SF-36 scores at 3 and 12 months, while amiodar-
one therapy did not show any impact on SF-36 scores.14 These
studies all highlight that amiodarone therapy did not worsen
HRQL as assessed by SF-36. Whether this was achieved,
however, through a direct effect of amiodarone, either by
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maintaining sinus rhythm or its rate controlling properties during
AF, on HRQL and/or through sinus rhythm maintenance remains
difficult to ascertain. In this respect, it is important to state that
drugs that possess rate controlling properties in addition to anti-
arrhythmic effects may have important advantages. The new anti-
arrhythmic drug, dronedarone, also contains this beneficial
combination of drug actions.15,16
The impact of major adverse events due to amiodarone therapy
on HRQL has, however, not been investigated before. Our results
showed a similar incidence rate of major adverse events after 12
months of follow-up in both treatment strategies [19 (25%) vs.
20 (24%), in the episodic and continuous group, respectively].
This may, in part, account for the comparable SF-36 scores after
12 months of follow-up found in both groups. In addition, even
though the episodic group had more patients with AF recurrence
the median number of recurrences per patient during 12 months
of follow-up was one in both treatment groups, resulting in
similar SF-36 scores.
Quality of life and sinus rhythm
In our study population QoL, assessed by SF-36 and AF severity
scale, improved significantly if sinus rhythm could be maintained,
but only in the episodic treated group. Significant QoL improve-
ments were seen on four subscales, with lower severity of
AF-related complaints in those who maintained sinus rhythm at
12 months of follow-up, indicating that sinus rhythm indeed
improves AF-related complaints. The positive benefit of sinus
rhythm maintenance in the episodic group may, however, have
been influenced by the timing of AF recurrence. AF recurrence
occurred relatively late (after a mean of 244 days) and close to
completion of the questionnaires and could therefore have had a
more substantial influence on outcome. Fewer patients in the epi-
sodic group, however, maintained sinus rhythm throughout
follow-up compared with patients treated with continuous amio-
darone. This was influenced by the fact that significantly fewer
patients in the episodic group were on amiodarone therapy at
12 months of follow-up. In line with these findings, Singh et al.17
also found significant improvements on various SF-36 subscales
in patients who maintained sinus rhythm compared with patients
in AF, with significant reduction in perceived AF severity. These
patients were all continuously treated with amiodarone. Dorian
et al.12 showed that scores on the AF severity scale decreased
more in the amiodarone group compared with the propafenone
and sotalol groups, probably due to the superiority of amiodarone
in sinus rhythm maintenance. We have also previously shown that
improvement in HRQL, assessed by SF-36 is associated with the
presence of sinus rhythm at the end of follow-up.4
Interestingly, patients in the continuous group, on the other
hand, had similar QoL improvement, both on the SF-36 scores
and the AF severity scale, independent of rhythm control
outcome. Even though continuous amiodarone treatment was
superior to episodic treatment for maintaining sinus rhythm, it
did not lead to vaster improvement in QoL. The positive benefit
of sinus rhythm maintenance on QoL may therefore have been
counterbalanced by daily amiodarone use. Alternatively, the
lower heart rate during recurrent AF in the continuous group,
due to the rate controlling property of amiodarone, may have
had favourable effects on QoL, as AF recurrences may have
been asymptomatic. We did not monitor for AF recurrences
between follow-up visits to systematically detect asymptomatic
Figure 2 Mean changes in SF-36 scores at 12 months from baseline in both treatment strategies according to rhythm control outcome. AF,
atrial fibrillation; HRQL, health-related quality of life; SF-36, Short Form-36 health survey; SR, sinus rhythm. *P, 0.05 maintenance of sinus
rhythm during follow-up vs. recurrence atrial fibrillation.
S. Ahmed et al.790
 at R








recurrences. This is also reflected by the larger improvement on
the subscale role limitations due to physical problems in patients
with AF recurrence on continuous amiodarone therapy. These
results suggest that substantial improvement in QoL is not
achieved by sinus rhythm maintenance alone, but especially by
sinus rhythm maintenance without the need for antiarrhythmic
drug use. This poses an interesting question for whom episodic
amiodarone treatment may be a viable therapy option for success-
ful rhythm control.
Study limitations
We studied QoL, using SF-36 and AF severity scale in a small study
population. The study was, however, a predefined sub-study of the
CONVERT study. Due to the small number of patients in this
study the power to detect differences between the two treatment
strategies and their effect on QoL is low. This was also further con-
founded by the exclusion of nearly a quarter of the cohort (51 out
of 209 patients), though they had comparable baseline character-
istics to the included patients. The results may have been different
with the inclusion of these patients. Our results regarding rhythm
control outcome and QoL are also based on a small number of
patients and are an analysis of a subset of patients. The conclusions
that have been drawn should, therefore, be interpreted with
caution and seen as hypothesis-generating. It cannot be generally
applied to all patients with persistent AF. We used the SF-36,
which is a validated questionnaire, but is a tool to measure
general HRQL. It may also measure complaints due to non-cardiac
diseases, and not only cardiac disease specific complaints.
Questionnaires were not filled out at the time of a recurrence
of AF or at the time of an amiodarone- or underlying heart
disease-related major adverse event, but at baseline and after
12 months. In addition, patients might have had asymptomatic AF
recurrences between follow-up visits, which were not detected.
The causal relationship between SF-36 and AF severity scale
scores and a recurrence of AF or occurrence of a major averse
event can therefore not be clearly established. Longer follow-up
may yield different results as the proportion of patients maintaining
sinus rhythm and the incidence of adverse events may be signifi-
cantly different.
Conclusions
In patients with persistent AF episodic amiodarone treatment is
not associated with higher QoL, assessed by SF-36 and AF severity
scale, compared with continuous amiodarone treatment. Success-
ful rhythm control outcome influenced QoL positively, but only in
the episodic treated group.
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